dabi

DABI can be used for relevant research in the life sciences. Its product number is T31179 and CAS number is 443-30-1.

Dabigatran etexilate (BIBR 1048) is a thrombin inhibitor that binds to thrombin, blocking its thrombogenic activity and preventing thrombus formation.

Dabigatran Etexilate Mesylate (BIBR 1048MS) is the orally active prodrug of dabigatran. Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI, Ki: 4.5 nM).

Dabigatran-D4 hydrochloride is deuterium-labeled dabigatran, which is a reversible and selective direct thrombin inhibitor (DTI) with a Ki value of 4.5 nM.

Dabigatran ethyl ester hydrochloride is an effective inhibitor of ribosyl dihydronicotinic acid amide dehydrogenase (NQO2) with an IC50 value of 0.8 μM and is a thrombin inhibitor.

Dabigatran ethyl ester (Dabigatran (ethyl ester)) is an emerging oral anticoagulant and it also is a direct inhibitor of thrombin activity.

Irdabisant (CEP-26401) (CEP-26401) is a selective, orally active and blood-brain barrier (BBB) penetrant antagonist/inverse agonist of histamine H3 receptor (H3R) (rat H3R Ki= 7.2 nM, human H3R Ki= 2.0 nM). Irdabisant exhibits relatively low inhibitory activity against hERG current (IC50= 13.8 μM). Irdabisant exhibits cognition-enhancing and wake-promoting activities in the rat social recognition model. Irdabisant can be used for research on schizophrenia or cognitive impairment.

Irdabisant hydrochloride (CEP-26401) is a selective, orally active, and blood-brain barrier penetrating histamine H3 receptor (H3R) inverse agonist, demonstrating high affinity with K*i values of 7.2 nM and 2.0 nM for rat and human H3R, respectively. Exhibiting relatively low hERG current inhibitory activity with an IC*50 of 13.8 μM, this compound has shown to enhance cognition and promote wakefulness in rat social recognition models, suggesting potential applications in schizophrenia or cognitive impairment research.

Dabigatran (BIBR 953ZW) is a THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.

Dabigatran acyl-β-D-glucuronide, an active metabolite of the thrombin inhibitor dabigatran, is synthesized predominantly through the action of the UDP-glucuronosyltransferase isoform UGT2B15. This compound, at a concentration of 0.46 µM, effectively prolongs activated partial thromboplastin time (aPTT) in isolated human platelet-poor plasma.

Dabigatran-D4 hydrochloride is a deuterated compound of Dabigatran Hydrochloride. Dabigatran Hydrochloride has a CAS number of 1019206-66-6.

Dabigatran-D4 hydrochloride is a deuterated compound of Dabigatran hydrochloride (TMSM-3464). Dabigatran hydrochloride has a CAS number of 211914-51-1. Dabigatran is a THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.

Dabigatran-D3 is a deuterated compound of Dabigatran (TMSM-3464).

Dabigatran-13C6 is the 13C labeled compound of Dabigatran. Dabigatran (T6295) has a CAS number of 211914-51-1. Dabigatran (T6295) is a THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.

Dabigatran-13C-D3 the 13C and deuterated compound of Dabigatran. Dabigatran has a CAS number of 211914-51-1. Dabigatran is a THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.

Dabigatran (Standard) is a reference standard for research and analysis in studies involving Dabigatran. Dabigatran (BIBR 953ZW) is a THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.

Dabigatran-13C6 (Standard) is a reference standard of Dabigatran-13C6 intended for quantitative analysis, quality control, and related biochemical research applications. Dabigatran-13C6 is the 13C labeled compound of Dabigatran. Dabigatran has a CAS number of 211914-51-1. Dabigatran is a THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.

Dabigatran-D4 Hydrochloride (Standard) is a reference standard of Dabigatran-D4 Hydrochloride intended for quantitative analysis, quality control, and related biochemical research applications. Dabigatran-d4 Hydrochloride is a deuterated compound of Dabigatran Hydrochloride. Dabigatran Hydrochloride has a CAS number of 1019206-66-6.

BIBR 1087 SE (Desethyl Dabigatran Etexilate) is a metabolite of dabigatran etexilate.

HadAB-IN-1, a potent inhibitor of the HadAB enzyme complex, exhibits significant activity by restraining mycolic acid biosynthesis in Mycobacterium tuberculosis (Mtb), with an inhibitory concentration (IC 50) value of 0.03 μM. This compound is utilized in tuberculosis (TB) research.